1. Home
  2. ICD-10-CM Codes
  3. E00–E89
  4. E70-E88
  5. E88
  6. 2026 ICD-10-CM Code E88.11

2026 ICD-10-CM Diagnosis Code E88.11

Partial lipodystrophy

ICD-10-CM Code:
E88.11
ICD-10 Code for:
Partial lipodystrophy
Is Billable?
Yes - Valid for Submission
Code Navigator:

E88.11 is a billable diagnosis code used to specify a medical diagnosis of partial lipodystrophy. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2025 through September 30, 2026.

Code Classification

  • Endocrine, nutritional and metabolic diseases
    E00–E89
    • Metabolic disorders
      E70-E88
      • Other and unspecified metabolic disorders
        E88

Approximate Synonyms

The following list of clinical terms are approximate synonyms, alternative descriptions, or common phrases that might be used by patients, healthcare providers, or medical coders to describe the same condition. These synonyms and related diagnosis terms are often used when searching for an ICD-10 code, especially when the exact medical terminology is unclear. Whether you're looking for lay terms, similar diagnosis names, or common language alternatives, this list can help guide you to the correct ICD-10 classification.

  • Acquired partial lipodystrophy
  • Acquired partial lipodystrophy
  • AKT2-related familial partial lipodystrophy
  • Autosomal semi-dominant severe lipodystrophic laminopathy
  • CIDEC-related familial partial lipodystrophy
  • Familial partial lipodystrophy
  • Familial partial lipodystrophy Dunnigan type
  • Familial partial lipodystrophy Kobberling type
  • Insulin resistance
  • Insulin resistance
  • LIPE-related familial partial lipodystrophy
  • Lipodystrophy, partial, with Rieger anomaly, short stature, and insulinopenic diabetes mellitus
  • Malabsorption of glucose
  • Malabsorption of glucose
  • Partial face-sparing lipodystrophy
  • Perilipin 1 related familial partial lipodystrophy
  • PPARG-related familial partial lipodystrophy

Clinical Information

  • Insulin Resistance

    diminished effectiveness of insulin in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

  • Metabolic Syndrome

    a cluster of symptoms that are risk factors for cardiovascular diseases and type 2 diabetes mellitus. the major components of metabolic syndrome include abdominal obesity; atherogenic dyslipidemia; hypertension; hyperglycemia; insulin resistance; a proinflammatory state; and a prothrombotic (thrombosis) state.

  • Acquired Partial Lipodystrophy

    partial lipodystrophy, the cause of which is not present at birth. examples include lipodystrophy associated with human immunodeficiency virus (hiv) therapy, and barraquer-simons syndrome, associated with c3 nephritic factor.

  • Familial Partial Lipodystrophy Type 2|FPLD2

    an autosomal dominant sub-type of familial partial lipodystrophy caused by mutation(s) in the lmna gene encoding prelamin-a/c.

  • Familial Partial Lipodystrophy|Congenital Partial Lipodystrophy

    an autosomal dominant inherited disorder that appears in childhood or adolescence. it is characterized by loss of adipose tissue in the extremities and accumulation of adipose tissue in the face and neck.

  • Partial Lipodystrophy

    loss and redistribution of subcutaneous and/or visceral adipose tissue from specific regions of the body.

  • Homeostatic Model Assessment of Insulin Resistance

    an assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.

  • Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome

    a condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. it is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.

  • Insulin Receptor Mutation - Associated Insulin Resistance Syndromes

    insulin resistance caused by inactivating mutation(s) in the insr gene encoding the insulin receptor.

  • Insulin Resistance

    decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.

  • Insulin Resistance Measurement|INSULINR|Insulin Resistance|Insulin Resistance

    the determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.

  • Insulin Resistance Syndrome

    a cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. these abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.

  • Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome

    a syndrome of insulin resistance caused by mutation(s) in the insr gene, encoding the insulin receptor. this condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. this is the least severe of a spectrum of disorders; the other two conditions are rabson-mendenhall syndrome and donohoe syndrome.

  • Obesity-Associated Insulin Resistance

    insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.

New 2026 ICD-10-CM Code

E88.11 is new to ICD-10-CM code set for the FY 2026, effective October 1, 2025. The National Center for Health Statistics (NCHS) has published an update to the ICD-10-CM diagnosis codes which became effective October 1, 2025. This is a new and revised code for the FY 2026 (October 1, 2025 - September 30, 2026).

Tabular List of Diseases and Injuries

The following annotation back-references are applicable to this diagnosis code. The Tabular List of Diseases and Injuries is a list of ICD-10-CM codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more.


Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Acquired partial lipodystrophy (APL)
  • Barraquer-Simons lipodystrophy
  • Familial partial lipodystrophy (FPLD)

Index to Diseases and Injuries References

The following annotation back-references for this diagnosis code are found in the injuries and diseases index. The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10-CM code(s).

Index of External Cause of Injuries

References found for this diagnosis code in the External Cause of Injuries Index:

    • APL(acquired partial lipodystrophy)
    • Barraquer(-Simons) disease or syndrome (progressive lipodystrophy)
    • Disease, diseased
      • Barraquer (-Simons') (progressive lipodystrophy)
    • Disease, diseased
      • Simons' (progressive lipodystrophy)
    • Lipodystrophia progressiva
    • Lipodystrophy
      • partial (acquired) (familial)
    • Lipodystrophy
      • progressive
    • Simons' disease or syndrome(progressive lipodystrophy)
    • Syndrome
      • Simons'

Replacement Code

E8811 replaces the following previously assigned ICD-10-CM code(s):

  • E88.1 - Lipodystrophy, not elsewhere classified

Code History

  • FY 2026 - Code Added, effective from 10/1/2025 through 9/30/2026